Premium
The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle‐aged men and differs from time trends in systemic diffuse large B‐cell non‐Hodgkin's lymphoma
Author(s) -
O'Neill Brian Patrick,
Decker Paul A.,
Tieu Christina,
Cerhan James R.
Publication year - 2013
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23551
Subject(s) - incidence (geometry) , medicine , primary central nervous system lymphoma , epidemiology , demography , diffuse large b cell lymphoma , population , relative survival , pediatrics , lymphoma , cancer registry , optics , physics , environmental health , sociology
There has been an overall decline in the United States incidence of Primary CNS Lymphoma (PCNSL) from 1998 to 2008. This study's intent was to characterize the cohorts contributing to it. First, calculated the PCNSL incidence rates from nine Surveillance, Epidemiology, and End Results (SEER) registries for time period 1973 to 2008. Second, examined the time trends overall and by age and gender. Third, used 1992–2008 SEER data from the same registries to obtain overall trends for diffuse large B‐cell lymphoma (DLBCL). Last, rates were age‐adjusted to the 2000 US standard population and reported per 100,000 person‐years. Rates continued to increase in women at all ages and men aged 65 and older. In men aged 20–39 and 40–64 years incidence rates peaked in 1995 and then declined dramatically, stabilizing after 1998. The trends in the incidence of PCNSL over this time frame were significantly different from DLBCL for ages 20–39 ( P < 0.001) and 40–64 ( P < 0.001) years but were not different for the 65 years and older age group ( P = 0.99). The overall PCNSL incidence rate declined since 1995 and was driven primarily by the changing incidence in young and middle‐aged men. The rate has continued to increase in men aged 65 years and older and in women. The trends in incidence in the younger age groups over this time period did not parallel those observed for DLBCL. Am. J. Hematol. 88:997–1000, 2013. © 2013 Wiley Periodicals, Inc.